Background. cGVHD is an inflammatory syndrome that affects >50% of long-term hematologic cancer survivors following allogeneic stem cell transplant. cGVHD can impact multiple organs, causing debilitating, unpredictable symptoms. To guide behavioral interventions for reducing symptom burden in this population, we explored two potential targets: general behavioral coping skills and self-efficacy for cGVHD management. Specifically, we examined associations of self-efficacy and coping skills with cGVHD symptom bother. Moreover, we explored the extent to which these associations may be moderated by disease-related factors, including cGVHD severity and time since transplant. Methods. We conducted a secondary analysis of baseline data from a prospective study of quality of life in allogeneic transplant survivors with moderate or severe cGVHD at an academic medical center (N=80). The baseline survey included demographic items and assessments of self-efficacy for cGVHD management (Communication & Attitudinal Self-Efficacy Scale), perceived coping skills (Measure of Current Status), and symptom bother (Lee cGVHD Symptom Scale). Multivariable linear regression was used to evaluate associations of self-efficacy and coping skills with symptom bother and whether these associations were moderated by cGVHD severity (moderate vs. severe) and months since transplant. Results. Among participants (M age=62 years, 50% male, 46% acute leukemia), neither cGVHD severity nor time in survivorship moderated the relationships of self-efficacy or coping skills with symptom bother (all interactions term p’s >.20). In final main effects models adjusting for cGVHD severity and time in survivorship, greater self-efficacy for managing cGVHD was associated with less symptom bother (Standardized b=-.32, 95% CI [-.55, -.18], p=-.015), whereas general coping skill was not (Standardized b=-.15, 95% CI [-.55, .18], p=.309). Conclusions. Greater self-efficacy for managing cGVHD, but not general coping skills, remained a key predictor of lower symptom bother independent of the severity of cGVHD or time in survivorship. Findings support the need to further explore disease-specific coping targets embedded in tailored behavioral interventions. Future work should examine this relationship longitudinally, including the extent to which specific self-management strategies (e.g., self-monitoring) may assist survivors in coping with the disruptive symptomatology of cGVHD across the survivorship continuum.